Abstract | BACKGROUND AND PURPOSE: EXPERIMENTAL APPROACH: GA was delivered by osmotic pumps in MI mice. Masson staining, electron microscopy (EM) and echocardiography were used to assess cardiac fibrosis, ultrastructure and function. Expression of SUMO-1, PML, TGF-β1 and Pin1 was measured with Western blot or Real-time PCR. Collagen content, cell viability and myofibroblast transformation were measured in neonatal mouse cardiac fibroblasts (NMCFs). Promyelocytic leukemia (PML) protein was over-expressed by plasmid transfection. KEY RESULTS: GA improved cardiac fibrosis and dysfunction, and decreased SUMO-1 expression in MI mice. GA (>20 μM) inhibited NMCF viability in a dose-dependent manner. Nontoxic GA (10 μM) restrained angiotensin II (Ang II)-induced myofibroblast transformation and collagen production. GA also inhibited expression of TGF-β1 mRNA and protein in vitro and in vivo. GA suppressed PML SUMOylation and PML nuclear body (PML-NB) organization, and disrupted expression and recruitment of Pin1 (a positive regulator of TGF-β1 mRNA), whereas over-expression of PML reversed that. CONCLUSIONS AND IMPLICATIONS: Inhibition of SUMO-1 by GA alleviated MI-induced heart dysfunction and fibrosis, and the SUMOylated PML/Pin1/TGF-β1 pathway is crucial for GA-inhibited cardiac fibrosis.
|
Authors | Fang Qiu, Changjiang Dong, Yanxin Liu, Xiaoqi Shao, Di Huang, Yanna Han, Bing Wang, Yanli Liu, Rong Huo, Petro Paulo, Zhi-Ren Zhang, Dan Zhao, Wen-Feng Chu |
Journal | Toxicology and applied pharmacology
(Toxicol Appl Pharmacol)
Vol. 345
Pg. 1-9
(04 15 2018)
ISSN: 1096-0333 [Electronic] United States |
PMID | 29524504
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2018. Published by Elsevier Inc. |
Chemical References |
- SUMO-1 Protein
- Salicylates
- ginkgolic acid
|
Topics |
- Animals
- Animals, Newborn
- Cell Survival
(drug effects, physiology)
- Dose-Response Relationship, Drug
- Fibrosis
(drug therapy, metabolism, pathology)
- Male
- Mice
- Myocardial Infarction
(drug therapy, metabolism, pathology)
- SUMO-1 Protein
(antagonists & inhibitors, metabolism)
- Salicylates
(pharmacology, therapeutic use)
- Stroke Volume
(drug effects, physiology)
|